Heroin effects on Nervous System (Mouse Party)
Credits for: learn.genetics.utah.eduFrom:Galves13Views:2 0ratingsTime:01:51More inEducation

Visit link:
Heroin effects on Nervous System (Mouse Party) - Video

Recommendation and review posted by Bethany Smith

The New World Of Genetics
From:cheonj1Views:1 0ratingsTime:07:38More inPeople Blogs

See the rest here:
The New World Of Genetics - Video

Recommendation and review posted by Bethany Smith

2020z warner beef genetics
From:Chris MitchellViews:0 0ratingsTime:00:59More inPets Animals

Originally posted here:
2020z warner beef genetics - Video

Recommendation and review posted by Bethany Smith

Genetics Project
Music- Question by Common and Mos Def Over My Dead Body by Drake Sound Effects from Apple Inc. Thanks Andrew Cole Survey ParticipantsFrom:OhKaylynViews:0 0ratingsTime:03:23More inPeople Blogs

Read more:
Genetics Project - Video

Recommendation and review posted by Bethany Smith

Part 3: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:11:17More inScience Technology

View original post here:
Part 3: Roundtable on Advanced Networking Initiatives in NC - Video

Recommendation and review posted by Bethany Smith

Part 2: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:09:16More inScience Technology

See the article here:
Part 2: Roundtable on Advanced Networking Initiatives in NC - Video

Recommendation and review posted by Bethany Smith

Part 1: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:10:19More inScience Technology

See the rest here:
Part 1: Roundtable on Advanced Networking Initiatives in NC - Video

Recommendation and review posted by Bethany Smith

Sequenced Pig Genome Creates Opportunities for Health Research
An international scientific collaboration that includes two CVM researchers is bringing home the bacon when it comes to potential animal and human health advancements, thanks to successfully mapping the genome of the domestic pig. The sequenced genome gives researchers a genetic blueprint of the pig. It includes a complete list of DNA and genes that give pigs their traits like height and color. Once all of the genetic information is understood, scientists anticipate improvements to the animal #39;s health as well as human health, as pigs and humans share similar physiologies. "With the sequenced genome we have a better blueprint than we had before about the pig #39;s genetics and how those genetic mechanisms work together to create, such as the unique merits in disease resistance," said Dr. Yongming Sang, research assistant professor in the Department of Anatomy and Physiology. For three years, Dr. Sang worked on the genome sequencing project with Dr. Frank Blecha, associate dean for the College of Veterinary Medicine and university distinguished professor of anatomy and physiology. A report of the international study appears as the cover story for the Nov. 15 issue of the journal Nature. To read more of the November issue of Lifelines, go to http://www.vet.k-state.eduFrom:KSUCVMViews:2 0ratingsTime:04:04More inEducation

See more here:
Sequenced Pig Genome Creates Opportunities for Health Research - Video

Recommendation and review posted by Bethany Smith

ROOFTOP MASSACRE (The Hidden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...From:SeaNannersViews:302 2425ratingsTime:02:59More inGaming

Read more:
ROOFTOP MASSACRE (The Hidden) - Video

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include compelling survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

"There are more than a dozen data presentations at ASH evaluating the use of ADCETRIS in CD30-positive malignancies and we are very encouraged by both the broad application across multiple hematologic disease areas as well as the encouraging activity associated with ADCETRIS, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The extensive investigator and corporate data presentations at ASH clearly demonstrate the important role ADCETRIS plays in the treatment of relapsed HL and systemic anaplastic large cell lymphoma and the promise of the role it potentially will play in additional future indications.

Long-term Survival Analysis of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #3689)

A pivotal, single-arm trial was conducted in 102 relapsed or refractory HL patients after ASCT to assess efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival and overall survival. Enrolled patients had received a median of more than three prior chemotherapy regimens.

Data highlights from the long-term survival analysis in the pivotal trial were:

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (Abstract #3701)

An independent retrospective comparison conducted by MD Anderson Cancer Center evaluated overall survival in 102 relapsed HL patients treated with ADCETRIS in a pivotal clinical trial compared to data from 756 relapsed HL patients treated at six international centers (Horning et al., 2008). The authors compared median overall survival, starting at the time of receiving an ASCT, among ADCETRIS treated patients to patients not treated with ADCETRIS. Key findings, which were highlighted in a presentation by Dr. Meghan Karuturi from MD Anderson Cancer Center, included:

Brentuximab Vedotin as a First Line Salvage Therapy in Relapsed/Refractory HL (Abstract #3699)

An investigator-sponsored trial was conducted to evaluate ADCETRIS as a salvage therapy for HL. Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with the chemotherapy regimens ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine hydrochloride, prednisone) or a combination of chemotherapy with or without consolidative radiation treatment. Patients were treated with ADCETRIS every three weeks for a maximum of four cycles. Data were presented by Dr. Robert Chen from City of Hope National Medical Center in Duarte, CA.

Read this article:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that results from two ongoing investigator-sponsored phase II clinical trials of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS has not been approved for use in the treatment of CTCL.

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression (Abstract #797)

The ongoing phase II clinical trial is enrolling CTCL patients with mycosis fungoides (MF) or Sezary syndrome. Twenty patients have been enrolled to date with a median of six prior systemic therapies. The primary endpoint of the trial is clinical response rate. Secondary endpoints include correlation of clinical response with CD30 expression levels, duration of response and safety. The study was led by principle investigator Dr. Youn H. Kim from Stanford University School of Medicine in Stanford, CA, and was presented in an oral session. Key findings include:

Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders (Abstract #3688)

Data were presented from a phase II investigator-sponsored trial evaluating the use of ADCETRIS in CD30-positive CTCL patients, including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The ongoing study is being conducted by Dr. Madeleine Duvic from The University of Texas MD Anderson Cancer Center in Houston, TX. Among 54 patients enrolled to date, 46 patients were evaluable at the time of analysis. The primary endpoint of the trial is to evaluate the safety and efficacy of ADCETRIS in CD30-positive CTCL. The key findings include:

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated the ALCANZA trial, a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least four months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the U.S. Food and Drug Administration (FDA). The study also received European Medicines Agency scientific advice.

About CTCL

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Cutaneous lymphomas are a category of non-Hodgkin lymphomas that primarily involve the skin. According to the Cutaneous Lymphoma Foundation, CTCL is the most common type of cutaneous lymphoma and typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood and internal organs. According to published literature, up to 50 percent of CTCL patients lesions express CD30.

About ADCETRIS

See more here:
Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma (HL) patients. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS is currently not approved for use in the front-line treatment of HL.

In the phase I trial, newly diagnosed patients received ADCETRIS concomitantly with either ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) or AVD, which removes bleomycin from the regimen. At the end of front-line therapy, 24 of 25 patients (96 percent) treated with ADCETRIS plus AVD and 21 of 22 (95 percent) patients treated with ADCETRIS plus ABVD had a complete remission. None of the patients treated in the ADCETRIS plus AVD cohort experienced pulmonary toxicity, compared with an expected rate of pulmonary toxicity caused by ABVD alone of 10-25 percent. The trial was designed to establish the safety profile and maximum tolerated dose when adding ADCETRIS to ABVD or AVD. Antitumor activity was assessed as a secondary endpoint.

"For over 30 years, the standard of care for front-line HL has been a chemotherapy regimen called ABVD that has demonstrated a complete remission rate of 70 to 80 percent and is associated with considerable life-threatening toxicities. There is a significant need to identify better treatment options for patients in the front-line HL setting, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Our goal is to redefine front-line treatment of HL with the addition of ADCETRIS, and the encouraging results of this phase I trial clearly support this goal and provide rationale for the ongoing ADCETRIS phase III trial in this setting."

Front-line Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma (Abstract #798)

In this open-label, multicenter trial, cohorts of patients received an escalating dose of ADCETRIS (0.6 milligrams per kilogram (mg/kg), 0.9 mg/kg, 1.2 mg/kg) every two weeks concomitantly with ABVD or a dose of 1.2 mg/kg every two weeks concomitantly with AVD.

Fifty-one patients were enrolled in the phase I study and 47 were evaluable for response at trial completion. The 47 evaluable patients included 25 in the ADCETRIS plus AVD cohort and 22 in the ADCETRIS plus ABVD cohorts. All patients were previously untreated and 45 percent had Stage IV HL. The median age of patients across all cohorts of the trial was 33 years. Key findings, which were highlighted in an oral presentation by Dr. Stephen Ansell, Professor of Medicine, Division of Hematology, from the Mayo Clinic, included:

For decades researchers have strived to improve our front-line HL treatment strategy by enhancing the activity of traditional chemotherapy regimens while reducing the significant toxicities and long-term side effects of such regimens, said Stephen Ansell,M.D., Ph.D., Professor of Medicine, Division of Hematology, Mayo Clinic. There is a significant need to identify better treatment options for patients in the front-line setting. With a complete response rate of 96 percent and a manageable safety profile, data from this trial support further evaluation of ADCETRIS administered concomitantly with AVD in previously untreated HL patients to potentially improve the current standard of care.

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated a phase III clinical trial in advanced stage front-line HL patients. The randomized trial is comparing progression-free survival in patients receiving ADCETRIS in combination with AVD to patients receiving ABVD alone. For more information about the trial visit http://www.seattlegenetics.com or http://www.clinicaltrials.gov.

About ADCETRIS

Originally posted here:
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today highlighted clinical data from two antibody-drug conjugate (ADC) programs in development by Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) that utilize Seattle Genetics technology. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Phase I data from both ADCs, an anti-CD22 ADC (DCDT2980S, RG7593) and an anti-CD79b ADC (DCDS4501A, RG7596), demonstrated antitumor activity in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) patients at generally well-tolerated doses. These ADC programs are currently being evaluated in a phase II clinical trial for patients with relapsed or refractory B-cell NHL.

Genentechs phase I data and their advancement of these two ADCs into phase II clinical development, as well as their utilization of our technology in six other clinical-stage programs,illustrates their commitment to ADCs as an innovative, targeted approach to treat cancer,saidEric Dobmeier, ChiefOperatingOfficer of Seattle Genetics. Across our ADC collaborations, there is broad potential for our industry-leading technologyto address thesignificant needformore effective and better tolerated treatment options.

Anti-CD22-MMAE and anti-CD79b-MMAE are ADCs designed to deliver potent cytotoxic treatment to targeted cells with improved tolerability. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), and stable linker systems that attach these cytotoxic agents to the antibody. Seattle Genetics linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. ADCETRIS (brentuximab vedotin) is the first drug approved utilizing Seattle Genetics ADC technology.

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #56)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDS4501A in patients with relapsed or refractory B-cell NHL. DCDS4501A is an ADC consisting of an anti-CD79b monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 47 patients were evaluable for safety and 32 were evaluable for efficacy.

Key findings included:

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #59)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDT2980S in patients with relapsed or refractory B-cell NHL. DCDT2980S is an ADC candidate consisting of an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 43 patients were evaluable for safety and 33 were evaluable for efficacy.

Key findings included:

View original post here:
Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting

Recommendation and review posted by Bethany Smith

TAINAN, Taiwan--(BUSINESS WIRE)--

The Society of Genetics, Genomics and Computational Biology had officially set up an education center at National Cheng Kung University (NCKU), southern Taiwan, to facilitate genetics and computational biology studies and to promote international interaction and communication in these fields, the university announced Dec. 5.

Dr. Chi-Chuan Hwang, chair of the education center, said that in order to promote research in these areas, the society had set up different teams based on different job contents, including the biology database team, the non-biological resource team, the computational biology skills team, the genetics team, the biotechnology team and the talent development team, and assigned people from the societys member countries to these teams.

The education center established at NCKU is focusing on talent cultivation, said Hwang, adding that the center hopes to recruit young students from different fields, including biology, medicine and engineering, in order to conduct interdisciplinary research.

With Fujitsu providing the hardware equipment, the first step taken by the education center was to ensure that the new software is capable of handling huge amount of data, and also to carry out the construction of gene pool and genome sequencing alignment, according to Hwang.

The Genomics and Bioinformatics course held on Dec. 3 was the first task of this education center.

Japans National Institute of Genetics (NIG) Deputy Director Takashi Gojobori, who is also Visiting Distinguished Chair Professor of NCKU, pointed out that efforts will be focused on the research of the variation of native species in Taiwan, especially the collection and analysis of seed gene pool, to build a complete gene sequencing database and also conduct a complete gene sequencing analysis on the collected genes.

Gojobori expected that these efforts would enhance NCKUs research capability and academic standards related to non-model species and biological diversity.

He hoped that by gathering different research capability, every team member will be able to make the greatest possible contribution to the conservation and protection of agriculture, ocean and natural environment.

The center will serve as an important platform for international interaction and communication in these fields, according to Gojobori, whose main purpose is not only to develop and nurture talent for research, but also to recruit domestic and foreign scholars to conduct education training and organize idea exchange sessions between member countries.

View post:
NCKU Sets up Genetics, Genomics, Computational Biology Education Center

Recommendation and review posted by Bethany Smith

Philippe Moullier, directeur scientifique Atlantic Gene Therapy #65279;
From:TelethontvViews:0 0ratingsTime:05:34More inNonprofits Activism

The rest is here:
Philippe Moullier, directeur scientifique Atlantic Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Innovation Presentation - Cancer Gene Therapy Project
NSW Health:bit.ly Media Release:bit.ly The Minister for Health, Jillian Skinner, hosted a community health forum in Parramatta on Wednesday 26 September 2012 to give Greater Western Sydney residents the chance to have their say on the future of health services in their community.From:NewSouthWalesHealthViews:0 0ratingsTime:06:48More inNonprofits Activism

The rest is here:
Innovation Presentation - Cancer Gene Therapy Project - Video

Recommendation and review posted by Bethany Smith

Ramsey Majzoub explains Gene Therapy Research conducted in the Safinya Group at UCSB
From:jennylei8Views:0 0ratingsTime:03:21More inPeople Blogs

See original here:
Ramsey Majzoub explains Gene Therapy Research conducted in the Safinya Group at UCSB - Video

Recommendation and review posted by Bethany Smith

Help Hemophilia of Georgia fund research for a cure
Families affected by hemophilia are anxiously waiting to find out if current gene therapy research will result in a cure. In this video, two fathers share what a cure would mean to their familiesFrom:HemophiliaOfGeorgiaViews:1 0ratingsTime:01:23More inNonprofits Activism

See the original post:
Help Hemophilia of Georgia fund research for a cure - Video

Recommendation and review posted by Bethany Smith

Melanoma, how can we have an earlier diagnosis? - Profesor Dréno
Interview of Professor Brigitte Dréno Vice Dean in charge of Research Faculty of Medicines Department of Dermato Cancerology Director Cell and Gene Therapy Unit Nantes Hospital University Giving her opinion on how to have an earlier diagnosis for melanoma.From:UVDAMAGELRPViews:2 0ratingsTime:03:45More inEducation

Go here to see the original:
Melanoma, how can we have an earlier diagnosis? - Profesor Dréno - Video

Recommendation and review posted by Bethany Smith

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

The Vaccine and Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Ted M. Ross, Ph.D., as Program Director. Dr. Ross will explore new vaccine technologies intended to protect against all strains of seasonal influenza. Such a vaccine could potentially eliminate the need for seasonal flu shots.

Traditionally, the flu vaccine is a mixture of inactive influenza viruses. However, Dr. Ross is taking a novel approach by examining the use of a synthetic vaccine created from genetic sequences of many different flu viruses. Dr. Ross previously used this method to produce a vaccine against the H5N1 virus, commonly known as the bird flu. The vaccine, well-tolerated in pre-clinical trials, successfully protects against known strains of bird flu. Dr. Ross and his VGTI Florida colleagues are applying similar strategies to fight other serious viruses such as West Nile Virus, Dengue and HIV Type 1 (HIV-1).

The holy grail of influenza vaccine research is a vaccine that protects against all influenza strains, avoiding the need for annual vaccinations, said Jay Nelson, Ph.D., founder and Executive Director, VGTI Florida. Were genuinely excited that Dr. Ross has joined us. His extensive background in immunology and microbiology will further benefit our efforts to develop vaccines that can help people with influenza, especially the elderly, added Dr. Rafick Skaly, Chief Scientific Officer and Co-Director of the institute.

Most recently, Dr. Ross was an Associate Professor, University of Pittsburgh School of Medicine, where he served in the Microbiology and Molecular Genetics department and was a full member of the Center for Vaccine Research. Prior to that, he was an Assistant Professor in the Department of Microbiology and Immunology at East Carolina University, School of Medicine in North Carolina.

Dr. Ross has co-authored numerous scientific articles published in journals such as Nature Immunology, The Journal of Virology, Journal of Infectious Disease, Vaccine, and the Proceedings of the National Academy of Sciences. He is a member of the American Society for Virology, American Society of Microbiology, Sigma Xi, International Society of Vaccines, and others. He holds B.S. and M.S. degrees from the University of Arkansas in Zoology and Microbiology, respectively. Dr. Ross earned his Ph.D. from Vanderbilt University in Microbiology & Immunology. Additionally, he was a Postdoctoral Fellow in HIV Research at Duke University and a Senior Research Associate in HIV Vaccine Research at Emory University.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer and HIV/AIDS. VGTI Florida is an independent non-profit 501 (c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

See the original post:
Dr. Ted Ross Joins the Vaccine & Gene Therapy Institute of Florida as Program Director

Recommendation and review posted by Bethany Smith

STAMFORD, Conn.--(BUSINESS WIRE)--

Alliance for Cancer Gene Therapy (ACGT), the nations only non-profit organization dedicated exclusively to funding cell and gene therapy research for cancer, is excited to play a major role in the recent leukemia study pioneered by scientists at the Perelman School of Medicine at the University of Pennsylvania. ACGT was the initial funding arm for the study using immune-mediated gene therapy for leukemia and lymphoma. This study illustrates the successful and sustained demonstration of how gene therapy uses the bodys own T-cells and turns them into weapons aimed directly at cancer.

Initial ACGT grants were awarded in 2004 to Dr. Carl June of the Abramson Family Cancer Research Institute at the University of Pennsylvania, and to Dr. Michel Sadelain, of Memorial Sloan-Kettering Cancer Center, Gene Therapy & Gene Expression Laboratory in New York City. Preliminary results were issued by Dr. Carl June and the University of Pennsylvania in August 2011, with additional results released this week and presented by Dr. Carl June at the American Society of Hematologys Annual Meeting and Exposition being held in Atlanta, Georgia.

The clinical trial participants, all of whom had advanced cancers, included ten adult patients with chronic lymphocytic leukemia, were treated at the Hospital of the University of Pennsylvania (HUP) and two children with acute lymphoblastic leukemia were treated at the Childrens Hospital of Philadelphia (CHOP). Two of the first three patients treated with the protocol at HUP whose cases were detailed in The New England Journal of Medicine and Science Translational Medicine in August 2011 remain healthy and in full remission more than two years after their treatment, with the engineered cells still circulating in their bodies. Currently, nine out of 12 of the participants show their disease in remission.

The discovery of successful cancer gene therapy treatments are what my husband and I hoped for when we founded ACGT a decade ago, noted Barbara Netter, president and co-founder of the Alliance for Cancer Gene Therapy. We knew it would be an uphill battle. ACGT was the only organization willing to take the risk when others were not. With federal funds decreasing, and the realization that pharmaceutical companies will not participate in the research phase until marketable and mass-produced treatments are created, we seized the chance to make a difference. My late husband Edward Netter (1932-2011), was a true visionary in the field of medical research. He would be so thrilled by the progress ACGT has made possible.

ACGT is currently funding 17 clinical trials in cancer cell and gene therapy targeting numerous types of cancers. Since its inception, ACGT has awarded more than $23 million in grants to 39 investigators to treat 11 different types of cancer. In 2012, ACGT also awarded a $500,000 grant to a clinical translational study on pancreatic cancer and has great expectations for its outcome. In ACGTs 2011 grant cycle, 87 scientists from throughout the U.S. responded with grant applications for ACGTs Young Investigator Grants, making 2011 one of the most sought-after funding year in ACGT history. The ACGT funded clinical studies are already showing promise, especially in the treatment of leukemia, lung, melanoma and prostate cancers.

It is so exciting that the pathfinder role ACGT played by provided the seed money for the University of Pennsylvania trial has led to these stunning successes for leukemia treatment, said Dr. Savio Woo, chairman of ACGTs Scientific Advisory Council, and founding Chair of the Department of Gene and Cell Medicine at Mt. Sinai School of Medicine in New York City.

Woo noted that 100 percent of all funds donated to ACGT go directly toward funding innovative cancer gene therapy research grants. ACGTs Scientific Advisory Council, which comprises some of the best scientific minds and thought leaders with major U.S. medical institutions, oversee all phases of the ACGT grant process. Through this rigorous review, ACGT is able to identify and fund studies with the most potential for positive and innovative outcomes for treating cancer using cell and gene therapy.

The University of Pennsylvanias initial study was funded primarily by ACGT. The most recent clinical trial was also supported by ACGT, the Leukemia & Lymphoma Society (Dr. June is the leader of one of the LLSs grants), and the National Institutes of Health. In addition, Novartis announced this summer that it would fund additional research at the University of Pennsylvania to further study the immunotherapies and has acquired exclusive rights to market the treatment.

Alliance for Cancer Gene Therapy (ACGT) is the nations only non-profit dedicated exclusively to cell and gene cancer therapy research. One hundred percent of all contributions to ACGT go directly to research and fund grants with leading scientists in the U.S., representing such institutions as Harvard Medical School, Johns Hopkins University School of Medicine, Mayo Clinic, St. Judes Childrens Hospital, Duke University, The Salk Institute, University of Pennsylvania, Memorial Sloan-Kettering, Stanford University, Dana Farber Cancer Center, University of California San Diego, University of Pittsburgh, and the University of Chicago. A rigorous grant review by Scientific Advisory Council ensures the most promising projects are rewarded. To learn more about the leukemia study at the University of Pennsylvania, and about the Alliance for Cancer Gene Therapy (ACGT), visit http://www.acgtfoundation.org or call 203.358.8000.

More:
Alliance for Cancer Gene Therapy Funds Promising Leukemia Study – Patients in Remission More Than Two Years after Gene ...

Recommendation and review posted by Bethany Smith

The Pathology Informatics Roadmap for Implementing Cancer Personalized Medicine- Michael Becich
From:PathinformaticsViews:2 0ratingsTime:41:58More inPeople Blogs

Read the original:
The Pathology Informatics Roadmap for Implementing Cancer Personalized Medicine- Michael Becich - Video

Recommendation and review posted by sam

Patrick Kitzman, PT, PhD "Community Network Development for Brain/Spinal Cord Injury and Stroke"
University of Kentucky College of Education Department of Kinesiology and Health Promotion Exercise Science Seminar Series Fall 2012 Biweekly on Fridays 9:00 - 10:00 AM 213 Seaton CenterFrom:Grant SandersViews:3 0ratingsTime:55:21More inEducation

More here:
Patrick Kitzman, PT, PhD "Community Network Development for Brain/Spinal Cord Injury and Stroke" - Video

Recommendation and review posted by sam

Luigi on the Spin Bike
Here is our client Luigi (C4-C5 spinal cord injury) pedaling a spin bike for the first time. By taking the handlebars off the bike, putting the high platform walker over the front wheel and using grip gloves, he is able to hold his trunk much more stable as well as hold himself for a much longer time, therefore getting a better push with his legs and for a longer duration. The trainer is spotting to make sure he doesn #39;t slide around on the seat too much, but that #39;s it! He is pushing the pedals all on his own! Go Luigi!From:pushtowalknjViews:0 0ratingsTime:01:36More inNonprofits Activism

Here is the original post:
Luigi on the Spin Bike - Video

Recommendation and review posted by sam

Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear!From:Deals2uTVViews:0 0ratingsTime:02:01More inHowto Style

The rest is here:
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage - Video

Recommendation and review posted by Bethany Smith